Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Blueprint Medicines Corporation BPMC NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
46/100
3/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$141.00
+8.9%

Blueprint Medicines Corporation (BPMC) is a Biotechnology company in the Healthcare sector, currently trading at $129.46. It has a SharesGrow Score of 46/100, indicating a mixed investment profile with 3 out of 7 criteria passed.

Analyst consensus target is BPMC = $141 (+8.9% upside).

Financials: revenue is $509M, +46.5%/yr average growth. Net income is $67M (loss), growing at +36.4%/yr. Net profit margin is -13.2% (negative). Gross margin is 96% (+6 pp trend).

Balance sheet: total debt is $469M against $299M equity (Debt-to-Equity (D/E) ratio 1.57, leveraged). Current ratio is 2.85 (strong liquidity). Debt-to-assets is 39.8%. Total assets: $1.2B.

Analyst outlook: 18 / 34 analysts rate BPMC as buy (53%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 60/100 (Pass), Growth 100/100 (Pass), Past 0/100 (Fail), Health 33/100 (Fail), Moat 70/100 (Pass), Future 52/100 (Partial), Income 10/100 (Fail).

$141.00
▲ 8.91% Upside
Average Price Target
Based on 34 Wall Street analysts offering 12-month price targets for Blueprint Medicines Corporation, the average price target is $141.00, with a high forecast of $150.00, and a low forecast of $132.00.
Highest Price Target
$150.00
Average Price Target
$141.00
Lowest Price Target
$132.00

BPMC SharesGrow Score Overview

54/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 60/100
Valuation — P/E, PEG, Forward PEG
GROWTH 100/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 33/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 70/100
Gross margin is + market cap
FUTURE 52/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — BPMC

✓
VALUE Pass
60/100
BPMC trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $141, implying +8.9% from the current price $129. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✓
GROWTH Pass
100/100
BPMC: +46.5%/yr revenue is, +36.4%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✗
HEALTH Fail
33/100
Balance sheet BPMC: Debt-to-Equity (D/E) ratio 1.57 (leveraged), Current ratio is 2.85 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✓
MOAT Pass
70/100
BPMC: Gross margin is 96% (+6 pp trend), $8B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 70/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
52/100
Analyst outlook: 18 / 34 analysts rate BPMC as buy (53%). Analyst consensus target is $141 (+8.9% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
BPMC: Net profit margin is -13.2%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range73.04-129.55
Volume2.98M
Avg Volume (30D)3.29M
Market Cap$8.36B
Beta (1Y)0.83
Share Statistics
EPS (TTM)-1.07
Shares Outstanding$62.86M
IPO Date2015-04-30
Employees682
CEOKathryn Haviland
Financial Highlights & Ratios
Revenue (TTM)$508.82M
Gross Profit$488.66M
EBITDA$19.23M
Net Income$-67.09M
Operating Income$-212.04M
Total Cash$615.49M
Total Debt$469.11M
Net Debt$367.09M
Total Assets$1.18B
Price / Earnings (P/E)-121
Price / Sales (P/S)16.43
Analyst Forecast
1Y Price Target$141.00
Target High$150.00
Target Low$132.00
Upside+8.9%
Rating ConsensusBuy
Analysts Covering34
Buy 53% Hold 44% Sell 3%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS09627Y1091

Price Chart

Track all markets on TradingView
BPMC
Blueprint Medicines Corporation ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
73.04 52WK RANGE 129.55

People Also View

KRTX
KRTX
Karuna Therapeutics, Inc.
$329.83
+0.03%
 MDGL
MDGL
Madrigal Pharmaceuticals, Inc.
$524.99
-0.13%
 KRYS
KRYS
Krystal Biotech, Inc.
$270.00
+0.97%
 PTCT
PTCT
PTC Therapeutics, Inc.
$73.01
+3.68%
 ISEE
ISEE
IVERIC bio, Inc.
$39.95
+0.38%
 TERN
TERN
Terns Pharmaceuticals, Inc.
$52.68
+0.13%
 DAWN
DAWN
Day One Biopharmaceuticals, Inc.
$21.46
-0.14%
 AMLX
AMLX
Amylyx Pharmaceuticals, Inc.
$16.92
+2.73%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message